NASDAQ:CTIC

CTI BioPharma Stock Forecast, Price & News

$2.40

-0.03 (-1.23 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.35

▼

$2.43

50-Day Range

$2.25

▼

$2.60

52-Week Range

$0.96

▼

$4.13

Volume281,618 shs

Average Volume793,966 shs

Market Capitalization$223.88 million

P/E RatioN/A

Dividend YieldN/A

Beta0.7

30 days | 90 days | 365 days | Advanced Chart

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

CTI BioPharma Corp. (DE) Common Stock (CTIC)
July 25, 2021 | nasdaq.com

CTI BioPharma Corp. (NASDAQ:CTIC) Expected to Post Earnings of -$0.20 Per Share
July 23, 2021 | americanbankingnews.com

CTI BioPharma (NASDAQ:CTIC) Stock Price Passes Above 200 Day Moving Average of $0.00
July 9, 2021 | americanbankingnews.com

CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Wednesday, June 16
June 9, 2021 | finance.yahoo.com

CTI BioPharma Reports First Quarter 2021 Financial Results
June 1, 2021 | finance.yahoo.com

CTI BioPharma Shares Shoot Higher as FDA Accepts Pacritinib Review Application In Bone Marrow Cancer
June 1, 2021 | finance.yahoo.com

CTI BioPharma : FDA Accepts NDA For Pacritinib As Treatment For Myelofibrosis Patient
June 1, 2021 | nasdaq.com

CTI BioPharma Gets FDA Priority Review of Pacritinib >CTIC
June 1, 2021 | marketwatch.com

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis
June 1, 2021 | finance.yahoo.com

7 Reddit Penny Stocks Promising to Cure Cancer
May 22, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
CIK891293
Webwww.ctibiopharma.com
Phone206-282-7100
Employees22
Year FoundedN/A

Sales & Book Value

Annual Sales$3.35 million
Price / Sales66.83
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.53 per share
Price / Book4.53

Profitability

EPS (Most Recent Fiscal Year)($0.74)
Net Income$-52,450,000.00
Net MarginsN/A
Return on Equity-135.08%
Return on Assets-95.67%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares93,282,000
Market Cap$223.88 million
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.80 out of 5 stars

Medical Sector

663rd out of 2,218 stocks

Pharmaceutical Preparations Industry

320th out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
CTI BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.38, CTI BioPharma has a forecasted upside of 249.0% from its current price of $2.40.
Amount of Analyst Coverage
CTI BioPharma has only been the subject of 2 research reports in the past 90 days.

3.2 Community Rank

Outperform Votes
CTI BioPharma has received 258 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CTI BioPharma has received 143 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CTI BioPharma has received 64.34% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote “Outperform” if you believe CTIC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CTI BioPharma does not currently pay a dividend.
Dividend Growth
CTI BioPharma does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CTI BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.50% of the stock of CTI BioPharma is held by insiders.
Percentage Held by Institutions
46.46% of the stock of CTI BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for CTI BioPharma are expected to grow in the coming year, from ($0.92) to ($0.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CTI BioPharma is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CTI BioPharma is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CTI BioPharma has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

Is CTI BioPharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTI BioPharma stock.
View analyst ratings for CTI BioPharma or view top-rated stocks.

What stocks does MarketBeat like better than CTI BioPharma?

Wall Street analysts have given CTI BioPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CTI BioPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for CTI BioPharma.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp. (NASDAQ:CTIC) announced its earnings results on Tuesday, June, 1st. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. During the same period in the prior year, the company earned ($0.19) EPS.
View CTI BioPharma's earnings history.

How has CTI BioPharma's stock been impacted by Coronavirus (COVID-19)?

CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CTIC shares have increased by 169.6% and is now trading at $2.40.
View which stocks have been most impacted by COVID-19.

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

Shares of CTI BioPharma reverse split before market open on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CTIC?

4 analysts have issued 12 month target prices for CTI BioPharma's stock. Their forecasts range from $5.50 to $15.00. On average, they expect CTI BioPharma's share price to reach $8.38 in the next year. This suggests a possible upside of 249.0% from the stock's current price.
View analysts' price targets for CTI BioPharma or view top-rated stocks among Wall Street analysts.

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the following people:

Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 55, Pay $1.03M)
Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 67, Pay $511.74k)
Mr. Bruce J. Seeley, Exec. VP & COO (Age 57, Pay $598k)
Mr. Ed Bell, Sr. Director of Investor Relations
Mr. Jim Fong, Sr. VP of Global Operations
Mr. Bruce K. Bennett Jr., Sr. VP Global Pharmaceutical Operations (Age 69)
Mr. John Volpone, Sr. VP of Strategic Operations
Dr. Jennifer A. Smith, Sr. VP of Biometrics

What is James A. Bianco's approval rating as CTI BioPharma's CEO?

8 employees have rated CTI BioPharma CEO James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among CTI BioPharma's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of CTI BioPharma's key competitors?

Some companies that are related to CTI BioPharma include Theravance Biopharma (TBPH), Omeros (OMER), Collegium Pharmaceutical (COLL), Ocular Therapeutix (OCUL), NRx Pharmaceuticals (NRXP), Pliant Therapeutics (PLRX), Design Therapeutics (DSGN), Keros Therapeutics (KROS), Enanta Pharmaceuticals (ENTA), ADVANZ PHARMA (CXRXF), GH Research (GHRS), Travere Therapeutics (TVTX), Bicycle Therapeutics (BCYC), Arcturus Therapeutics (ARCT) and Prometheus Biosciences (RXDX).
View all of CTIC's competitors.

What other stocks do shareholders of CTI BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $2.40.

How much money does CTI BioPharma make?

CTI BioPharma has a market capitalization of $223.88 million and generates $3.35 million in revenue each year. The biopharmaceutical company earns $-52,450,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does CTI BioPharma have?

CTI BioPharma employs 22 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is www.ctibiopharma.com.

Where are CTI BioPharma's headquarters?

CTI BioPharma is headquartered at 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here